Platinum Equity, a Southern California private equity firm, will buy Johnson & Johnson's LifeScan Inc. blood glucose monitoring device business for $2.1bn. The move, announced March 16, comes as no surprise. J&J announced in the beginning of 2017 that it was exploring strategic options for its shrinking diabetes businesses. Also see "Earnings Winners & Losers: Billion-Dollar-Revenue Players JNJ, ABT, GE, PHG, BAX" - Medtech Insight, 8 February, 2018.
"This initiative is part of our ongoing, disciplined approach to portfolio management to focus on our most promising opportunities to...







